David Capital Partners' Adam Patinkin on how Lifecore $LFCR has differentiated it's CDMO business
Summary
Adam Patinkin frames Lifecore as a classic “value plus a catalyst” investment: a deeply discounted business whose underlying quality and earnings power are now changing. Once buried inside Landec’s collection of low-margin agriculture businesses, Lifecore is finally a pure-play contract development and manufacturing organization. Patinkin and host Andrew Walker both disclose long positions.
CDMOs are attractive because drug manufacturing is mission-critical, inexpensive relative to total drug-development costs, and painfully difficult for customers to move. Switching facilities can require new FDA approval, while Lifecore has retained some customers for 40 years; Patinkin calls CDMOs the pharmaceutical industry’s “picks and shovels.” Good businesses have historically commanded 20x-plus EBITDA, with three cited transactions at 31x, 27x, and 45x.
Lifecore’s specialty—sterile fill-finish manufacturing for complex, highly viscous injectables—combines scarce technical expertise with a capacity-constrained market. Patinkin says more than half of recent FDA drug approvals have been injectables, GLP-1 sales are expected to increase tenfold by 2032, and new manufacturing capacity can take five years to install and approve. Lifecore has never received an FDA 483 warning letter and is sole-source for numerous customers.
The bear case is that investors have heard the same “great CDMO” story for years while revenue stalled, margins deteriorated, a sale process failed, and the stock fell from roughly $11 at year-end 2021 to $6.60 in March 2025. Patinkin attributes that record to divestiture turmoil, immaterial but protracted restatements, a year without current financials, weak capitalization, and an Alcon inventory destock that may have affected revenue by $10 million or more. His differentiated claim is that “the past and the future don’t look the same.”
The new CEO is applying a playbook he previously used three times to professionalize under-managed CDMOs. Management reorganized personnel, ended costly consulting arrangements, installed operational KPIs, recruited executives, and expanded business development. Lifecore guides EBITDA margins from roughly 15% to at least 25% within three years; Patinkin believes operating leverage could take them above 30%.
The largest upside lever—and biggest timing debate—is more than $300 million of annual revenue capacity against only about $130 million of current revenue. Newly installed capacity received final certification only in Q4, leaving Lifecore near 40% revenue-capacity utilization and, under another unit-based measure, roughly 20%. Patinkin points to five new-customer wins, a record pipeline, guaranteed contractual step-ups worth an estimated 5%-7% annual growth, and several filling routes; Walker counters that sticky incumbent relationships mean utilization “can’t just” appear overnight.
Execution and leverage remain capable of breaking the thesis before operating leverage proves it. Lifecore carries roughly $150 million of debt plus preferred securities, and Walker warns that another 18 months of stumbling could leave little room for a second chance. Patinkin says an October PIPE and inventory sale added more than $40 million of liquidity, but still identifies execution, the balance sheet, and the new CEO’s first stint as a public-company CEO as the principal risks.
Patinkin’s illustrative upside ranges from about $25 to nearly $40 per share, but he expects Lifecore to be acquired before either the business or stock reaches its theoretical endpoint. His math uses roughly 45 million fully diluted shares, a $6.50 stock, $450 million of enterprise value, and a path toward $50 million-$60 million of EBITDA; Avid Bioservices reportedly sold for 6.2x revenue versus Lifecore near 3x. Most strikingly, Lifecore used an 80% probability of a change-of-control event by 2028 in a January filing calculation—a disclosure Patinkin calls evidence that “the company knows the endgame.”
Deep dive
1. Lifecore emerged as the crown jewel inside an unlikely agriculture conglomerate
David Capital searches developed markets for “value plus a catalyst”: securities that are cheap today but possess an identifiable event path toward fair value. Patinkin prefers fundamental catalysts—better operations, higher profitability, and a business becoming worthy of a higher multiple—to traditional financial engineering. Lifecore, he argues, offers all three.
Landec’s original technology extended the shelf life of produce, but food companies reportedly resisted because “their best customer wasn’t the consumer…their best customer was the garbage bin.” Unable to commercialize the packaging directly, Landec bought guacamole, olive-oil, vegetable, salad, and hydroponics businesses, creating a volatile, seasonal, commodity-heavy conglomerate whose analysts sometimes tried to forecast the green-bean harvest.
Landec acquired Lifecore in 2010 to provide stability. While the agriculture operations struggled, the Minnesota CDMO delivered mid-teens top-line growth and mid-20% EBITDA margins over roughly a decade. When David Capital met management in 2018, the CFO still emphasized packaging; Patinkin’s response was effectively: Lifecore is “your crown jewel business,” so why keep focusing elsewhere?
Legion Partners reached the same conclusion in 2019, arguing that Lifecore alone was probably worth more than Landec’s enterprise value. Shareholders supported selling the agriculture assets and becoming a pure-play CDMO, but the decision arrived just before COVID disrupted operations, buyer appetite, and expected divestiture proceeds. The last agriculture sale was not completed until the end of 2022.
2. Accounting chaos obscured Lifecore without changing cash balances
The subsequent restatement concerned accounting for already-divested businesses, not Lifecore’s CDMO operations. Worse, the auditor reportedly reversed its position after the first restatement and required another—something Patinkin says he had “never ever seen” across thousands of companies. The adjustments were immaterial, involved no fraud or cash changes, yet pushed the company dark for a year and nearly cost its Nasdaq listing.
By 2024, the “storm clouds” finally began clearing: Lifecore completed the divestitures, caught up on financial statements, regained Nasdaq compliance, overhauled its board, and replaced both CEO and CFO. Its strategic sale process had occurred while the company was dark and near delisting, which Patinkin considers a poor setup for extracting an acceptable transaction—not evidence the asset itself was unwanted.
Walker’s pushback—worth keeping—is that the stock traded around $11 on December 31, 2021, versus roughly $6.60 in late March 2025, while neither margins nor recent revenue validated the long-promised transformation. Patinkin agrees the share price followed weak reported performance: “Of course the share price is going to be lower in that set of circumstances.”
The disagreement is prospective. Walker treats the missing historical proof as a reason for caution; Patinkin argues the market is valuing future financials as though nothing changed. “The past doesn’t matter anymore,” he says—not literally, but because the board, leadership, capitalization, sales cadence, and operating systems are now materially different.
3. CDMO economics rest on regulation, switching costs, and customer longevity
A CDMO—contract development and manufacturing organization—makes drugs for biotechnology and pharmaceutical companies. Drug developers commonly outsource because manufacturing requires specialized facilities, technical scale, capital, and exhaustive regulatory approval, all outside their core research and commercialization skills. Even large pharmaceutical companies outsource significant, sometimes majority, portions of production.
Quality matters disproportionately because manufacturing failure can harm patients, while manufacturing itself is only a low-single-digit percentage of the total cost of bringing a drug to market. Customers will therefore pay more for a long operating history and strong regulatory record: “They don’t want their clients to die when they take the drug.”
Walker stresses that the approved manufacturing site is embedded in the regulatory regime. Moving a drug can require fresh FDA work, new tests, and a process lasting more than a year; unless the incumbent performs badly, savings rarely justify the headache. Lifecore has customers that have been with it for 40 years, illustrating why CDMO revenue can be both recurring and unusually predictable.
Patinkin describes CDMOs as the pharmaceutical gold rush’s “picks and shovels”: diversified exposure to clinical and commercial drugs rather than a binary wager on one molecule. The industry reportedly grows 8%-9% annually, good operators earn 30%-plus EBITDA margins, and cited transactions occurred at 31x, 27x, and 45x EBITDA. Of four U.S.-listed CDMOs at the start of 2024, three were subsequently acquired.
4. Lifecore occupies a difficult and capacity-constrained injectable niche
Lifecore performs sterile fill-finish work for complex injectables, including substances closer to “maple syrup or molasses” than water. It must place these viscous drugs into vials, cartridges, or prefilled syringes across millions of doses without contamination or impurities—a capability Patinkin says leaves numerous customers with no equivalent alternative.
Injectables are described as the fastest-growing pharmaceutical vertical, representing more than half of recent FDA drug approvals. GLP-1 products such as Wegovy and Ozempic are expected to increase sales tenfold by 2032, further tightening fill-finish supply. New capacity generally takes five years to add—perhaps three or four “if you run a sprint”—and CDMOs rarely build without contracted demand.
Lifecore brings a 40-plus-year regulatory history and, according to Patinkin, has never received an FDA 483 warning letter. Its largest customer is Alcon, described as the world’s leading eye-care provider and a roughly $40 billion company; its Minnesota location sits in “Medical Alley,” amid more than 1,000 healthcare companies and over 500,000 healthcare workers.
5. Professional management is the margin catalyst the old organization lacked
Patinkin uses a roughly 160-person organizational threshold: below it, people can know nearly everyone; above it, informal “mom-and-pop” processes stop scaling. Lifecore reached 200-300 employees without making that transition. Fully costing corporate expenses left EBITDA margins in the mid-teens, about half the 30%-plus level he associates with capable peers.
The new CEO previously ran the larger, private-equity-backed Woodstock CDMO and had, in Patinkin’s telling, three times taken under-managed CDMOs and “whipp[ed] it into fighting shape.” New CFO Ryan Lake had been a public-company CDMO CFO and helped sell another listed operator for a premium exceeding 100%.
The inherited organization had overlapping roles, consultants filling gaps at “triple the costs,” and insufficient KPI tracking. New management reorganized reporting lines, ended consulting contracts, recruited stronger executives, and installed measures around manufacturing cycles, procurement, yields, and business development. It also built a properly resourced sales organization.
Management guides from approximately 15% EBITDA margins to at least 25% over three years. Patinkin views that target as conservative: operational discipline should lift the base, while incremental revenue against already-installed capacity carries very high margins. Together, he thinks those levers can eventually produce 30%-plus EBITDA margins.
6. Alcon normalization and contractual minimums could restart growth before new capacity fills
Lifecore’s current fiscal-year stall partly reflects Alcon’s company-wide working-capital program. Alcon continued selling inventory but temporarily paused orders, costing Lifecore perhaps $10 million or more of revenue. Excluding that event, Patinkin argues, Lifecore would have shown respectable year-over-year growth rather than an apparently flat business.
Because Alcon is public, Patinkin points to accelerating growth and improved inventory as evidence that its Lifecore ordering should return toward trend “pretty soon.” That remains an expectation, not a disclosed commitment, but it supplies one route from zero growth toward a meaningful near-term rebound.
Management has also begun writing guaranteed minimum volume increases into customer contracts. Patinkin estimates those step-ups alone can support 5%-7% annual revenue growth over the next several years. Combined with Alcon’s return, they could generate double-digit growth before major new-program revenue contributes.
Lifecore itself guides to at least 12% average annual revenue growth over three years. The market, Patinkin argues, still sees a company producing roughly $130 million of revenue and $20 million of EBITDA with no current-year growth; his thesis depends on that backward-looking snapshot breaking sharply from what follows.
7. New capacity creates enormous operating leverage, but sales cannot be rushed
After ordering capacity on speculation in 2019, Lifecore spent five years installing and qualifying it. The company now has more than $300 million of annual revenue capacity against approximately $130 million of sales—about 40% utilized on that basis. Its November 2024 presentation separately showed 40 million FY25 units, or roughly 20% unit capacity utilization, with a medium-term objective of 40% and a longer-term objective of 100%.
Walker finds it remarkable that the operation is EBITDA-positive at 20% utilization, but disappointing that an allegedly supply-starved market has not produced more announced wins. Patinkin’s timing rebuttal: the equipment received GMP approval only in Q4, less than 100 days before the conversation. Serious negotiations, site visits, vetting, contracting, and eventual revenue could not begin in earnest beforehand.
Management reports a record pipeline, particularly among large global pharmaceutical companies, and had announced about five customer wins under the new team, including one the prior week. That latest contract was a technology transfer from another company—evidence that switching an existing product, while difficult, is possible.
Lifecore can fill capacity through more than competitive displacement: additional drugs from qualified customers, progression from Phase 1 through commercialization, new clinical candidates, technology transfers, and second-source production for manufacturers lacking redundant capacity. Early-stage runs carry higher margins despite lower volumes; commercial programs bring scale. Patinkin calls eventual filling “inevitable,” while conceding it cannot happen by “snap[ping] your fingers.”
8. Policy may help, but execution and leverage remain the thesis-breaking risks
On the BIOSECURE Act, Patinkin says Lifecore does not directly overlap much with the targeted Chinese manufacturers, so near-term benefit may be limited. Longer term, however, restrictions on overseas manufacturing could force pharmaceutical companies to prioritize domestic partners. Lifecore’s entire manufacturing footprint is in Minnesota, placing it directly within that potential reshoring tailwind.
Walker’s counterweight is uncertainty around RFK: customers contemplating 15-year manufacturing relationships may hesitate without clarity on drug pricing, Medicare, Medicaid, or which products regulators will support. Patinkin does not know the answer, but argues the administration seeks more medical innovation, and broader support for generics, vitamins, hormones, or other neglected treatments “might actually cause there to be more demand for CDMOs.”
Patinkin names execution as the primary risk. Professionalization demands cultural as well as operational change, and sales contracts still must be signed. The new CEO has executed the playbook in private CDMOs but is a first-time public-company CEO who must communicate well, meet stated targets, and earn the market reputation he does not yet possess.
The balance sheet compounds every operating risk: roughly $150 million of debt, preferred securities, and a history of support from Alcon and investors. An October PIPE—joined by David Capital—and an inventory sale supplied over $40 million of liquidity. Patinkin calls the balance sheet its strongest in half a decade; Walker warns another 18-month stumble could mean “you don’t get a second chance.”
9. Incentives, valuation, and an 80% change-of-control estimate point toward a sale
Legion helped align management unusually tightly with shareholders. Beginning around $7.50, the CEO and CFO receive equity awards at successive $2.50 stock-price increases; Patinkin describes 100,000 shares for the CEO at each threshold along a schedule extending toward $40. The package could create “generational wealth,” but nothing pays below the initial hurdle.
Patinkin’s clean capitalization assumes roughly 45 million shares after converting the preferreds. At $6.50, that is just under $300 million of equity value; adding approximately $150 million of debt gives about $450 million of enterprise value. Current EBITDA is around $20 million, while the company trades at roughly 3x EV/revenue.
Management’s three-year targets imply revenue approaching $200 million by 2028. At 25% EBITDA margins, that produces about $50 million; at Patinkin’s 30% expectation, roughly $60 million. Applying 20x to $60 million yields $1.2 billion of enterprise value and, after perhaps $100 million of remaining debt, about $25 per share; 30x approaches $40.
Patinkin doubts Lifecore remains independent long enough to realize that endpoint. Avid Bioservices reportedly sold at 6.2x revenue versus Lifecore’s roughly 3x, while Lifecore’s January filing assigned an 80% probability to a change of control by 2028 when valuing a security. His closing frame: it is “a race against time” until a CDMO platform or private-equity buyer makes “an offer that Lifecore can’t refuse.”